News Release

Suven completed Phase-I Clinical Trials Single Ascending Dose of SUVN-502 in Switzerland

HYDERABAD, INDIA (September 29, 2008) – Suven Life Sciences Ltd today announced that it has completed the Phase-I single ascending dose study of SUVN-502 in healthy subjects. SUVN-502 is a potent, safe, highly selective, brain penetrant and orally active antagonist at a nonperipheral CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer’s disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson, Schizophrenia. The study was conducted at Basel, Switzerland under a Clinical Trial Application (CTA) approved by SwissMedic, the regulatory authority of Switzerland for therapeutic products. The study is “A Double-blind, placebo-controlled, randomized, single ascending dose study” in healthy male subjects.

The tolerability of SUVN-502 up to the highest dose administered is very good. No serious adverse events occurred. No clinically significant changes or study medication related abnormalities were observed with respect ECGs and laboratory evaluations. There were no clinically significant changes of vital sign parameters. The detailed pharmacokinetics of the SUVN-502 was studied from the blood samples drawn up to 72 hours post-dosing. SUVN-502 demonstrated very favorable pharmacokinetics with a potential for once in a day dosing.

"We are very pleased with the results of Phase-1 single ascending study with SUVN-502 in Switzerland. We believe that SUVN-502 has great potential to become a novel treatment for disorders affecting memory and cognition in Alzheimer’s and other dementia. SUVN-502 is the first NCE of Suven to enter the clinic from a pipeline of six NCEs. The CNS market and especially the cognition is amongst the largest, about $20 billion potential market opportunity globally and this novel target presents an excellent opportunity." says Venkat Jasti, CEO of Suven Life Sciences Ltd.

"The outcome of the Phase-I study is very much in-line with our predictions from the pre-clinical studies. SUVN-502 is a very safe molecule and has demonstrated to be highly potent, safe and orally available with good bioavailability across species tested. The molecule also exhibited excellent selectivity over other targets”. Says Dr. Ramakrishna Nirogi, Vice President, Discovery Research, Suven Life Sciences.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally discovered therapeutic drug candidates currently in clinical and pre-clinical stage of development targeting conditions such as ADHD, dementia, and depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidates in Alzheimer's disease and Schizophrenia.

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;